PolyPid Ltd
NASDAQ:PYPD
PolyPid Ltd
NASDAQ:PYPD
Price:
4.4
USD
5.01%
Market Closed
Market Cap:
$84m
PolyPid Ltd
Inventory
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
PolyPid Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Inventory
$1.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Inventory
$3.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Inventory
$4.1m
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
9%
|
|
|
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Inventory
₪41.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Inventory
₪96.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
No Stocks Found
PolyPid Ltd
Glance View
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
PYPD
Intrinsic Value
4.87
USD
Undervaluation 10%
See Also
What is PolyPid Ltd's Inventory?
Inventory
1.1m
USD
1.1m
USD
Based on the financial report for Dec 31, 2025, PolyPid Ltd's Inventory amounts to 1.1m USD.
